These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 26558391

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 4. Quantitative analysis of standardized uptake values (SUV) of metastatic bone lesions in scintigraphy with [99mTc]Tc-EDDA/HYNIC-Tyr3-octreotide in patients with neuroendocrine tumours.
    Malarz MM, Birkenfeld B, Piwowarska-Bilska H.
    Nucl Med Rev Cent East Eur; 2024; 27(0):31-35. PubMed ID: 39162352
    [Abstract] [Full Text] [Related]

  • 5. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ.
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [Abstract] [Full Text] [Related]

  • 6. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, Mikolajczak R, Zorga P.
    J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR.
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
    Qiao Z, Zhang J, Jin X, Huo L, Zhu Z, Xing H, Li F.
    Clin Nucl Med; 2015 May; 40(5):397-400. PubMed ID: 25706799
    [Abstract] [Full Text] [Related]

  • 13. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
    Li F, Chen LB, Jing HL, Du YR, Chen F.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
    [Abstract] [Full Text] [Related]

  • 14. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
    Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, Maecke HR, Walecki J.
    J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
    [Abstract] [Full Text] [Related]

  • 15. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
    Gómez M, Ferrando R, Vilar J, Hitateguy R, López B, Moreira E, Kapitán M, De Lima F, Agüero B, Gabriela Villegas M, Urdaneta N, Gutiérrez E, Battegazzore A, Bayardo K, Silveira A, Lago G, Páez A.
    Acta Gastroenterol Latinoam; 2010 Dec; 40(4):332-8. PubMed ID: 21381408
    [Abstract] [Full Text] [Related]

  • 16. Optimized method for normal range estimation of standardized uptake values (SUVmax, SUVmean) in liver SPECT/CT images with somatostatin analog [99mTc]-HYNIC-TOC (Tektrotyd).
    Piwowarska-Bilska H, Kurkowska S, Birkenfeld B.
    Nucl Med Rev Cent East Eur; 2022 Dec; 25(1):37-46. PubMed ID: 35137936
    [Abstract] [Full Text] [Related]

  • 17. Uptake in the pancreatic uncinate process on the 111In-octreotide scintigraphy: How to distinguish physiological from pathological uptake?
    Ait Boudaoud A, Verges B, Petit JM, Tatulashvili S, Cochet A, Humbert O.
    Nucl Med Commun; 2017 Sep; 38(9):737-743. PubMed ID: 28704340
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide: Incidence and Mechanism.
    Brabander T, Teunissen J, Kwekkeboom D.
    Clin Nucl Med; 2017 Jan; 42(1):15-19. PubMed ID: 27775943
    [Abstract] [Full Text] [Related]

  • 20. Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors.
    Sepúlveda-Méndez J, de Murphy CA, Pedraza-López M, Murphy-Stack E, Rojas-Bautista JC, González-Treviño O.
    Nucl Med Commun; 2012 Jan; 33(1):69-79. PubMed ID: 21970835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.